摘要
目的:分析免疫功能正常的中国人原发性中枢神经系统淋巴瘤(PCNSL)的临床资料,探讨PCNSL的临床特征,评价大剂量甲氨蝶呤(HD-MTX)加全脑放疗(WBRT)治疗PCNSL的疗效。方法:回顾性分析34例经病理证实的PCNSL患者的临床资料以及治疗效果,Kaplan-Meier法分析患者生存期。结果:34例PCNSL患者中B细胞淋巴瘤31例(91.2%),T细胞淋巴瘤3例(8.8%);所有患者治疗后评价完全缓解率(CR)41.2%,2年生存率60.2%;病理类型和是否接受HD-MTX加放疗是影响PCNSL生存期的主要原因(P<0.05)。结论:PCNSL以颅内高压为主要表现,B细胞亚型占绝对优势,具有独特的预后因素,HD-MTX联合放疗是PCNSL有效的治疗方法。
Objective： To investigate the clinical features of primary central nervous system lymphoma（PCNSL）, evaluate the efficacy of high-dose methotrexate（MTX）-based chemotherapy combining with whole brain radiation therapy （WBRT） for immunocompetent Chinese patients with PCNSL. Method： Clinical data of 34 patients that were pathologically diagnosed with PCNSL was analyzed retrospectively, and Kaplan-Meier method was used to calculate survival time. Result： Among 34 PCNSL patients, 31 （91.2%） were diagnosed with B-cell lymphoma, 3 （8.8%）T-cell lymphoma. The complete remission rate of treatment was 41.2%, and the 2-year survival rate was 60.2%. The overall survival time showed statistic correlation with tumor pathological type and the type of treatment patient received. Conclusion： The major clinical symptom of PCNSL is intracranial hypertension and it is considered as an important factor that affects the disease progression and prognosis. B-cell lymphoma is the predomi- nant subtype of PCNSL and combination of High-dose MTX-based chemotherapy with whole brain irradiation treatment is a more efficient approach.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第16期924-927,共4页
Chinese Journal of Clinical Oncology
